ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,04%
Bitcoin
67.123,56
0,27%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. VBI Vaccines Inc (VBIV)

  7. VBI Vaccines Inc (VBIV) News

VBIV

VBI Vaccines (VBIV)

VBI Vaccines Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VBIV
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202422h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
15/05/202422h00Business WireVBI Vaccines Reports First Quarter 2024 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
16/04/202414h00Business WireVBI Vaccines Reports Full Year 2023 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
11/04/202422h05Business WireVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:VBIVVBI Vaccines Inc
09/04/202420h45Business WireVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:VBIVVBI Vaccines Inc
03/04/202414h00Business WireVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaNASDAQ:VBIVVBI Vaccines Inc
02/04/202414h00Business WireVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformNASDAQ:VBIVVBI Vaccines Inc
14/02/202414h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
14/02/202413h00Business WireVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesNASDAQ:VBIVVBI Vaccines Inc
06/02/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
23/01/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
11/01/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/12/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
12/12/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
29/11/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
20/11/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
20/11/202314h00Business WireVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNASDAQ:VBIVVBI Vaccines Inc
14/11/202322h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
14/11/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VBIVVBI Vaccines Inc
14/11/202322h05Business WireVBI Vaccines Reports Third Quarter 2023 Financial ResultsNASDAQ:VBIVVBI Vaccines Inc
03/11/202322h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/10/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
26/10/202314h00Business WireVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramNASDAQ:VBIVVBI Vaccines Inc
27/09/202313h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
27/09/202313h30Business WireVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernNASDAQ:VBIVVBI Vaccines Inc
07/09/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
07/09/202314h00Business WireVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMNASDAQ:VBIVVBI Vaccines Inc
06/09/202315h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VBIVVBI Vaccines Inc
06/09/202314h00Business WireVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BNASDAQ:VBIVVBI Vaccines Inc
14/08/202314h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VBIVVBI Vaccines Inc
 Showing the most relevant articles for your search:NASDAQ:VBIV

Kürzlich von Ihnen besucht

COIN
BTTKRW
ASX
AOMDC
ASX
HFRJOA
USOTC
MEIUY
Meitu (PK)
COIN
SWZLUST
SwapZilla
EU
T716S
T716S
LSE
0IZ0
Grand Harbour Marina
LSE
XSX6
Xstoxeu600
COIN
BRICBTC
BIT
UB30DJ
UniCredit Bank
TSXV
BSI
Blue Sky Energy
BIT
F12904
Vontobel Financial Produ...
TSXV
CZ
Cassius Ventures Ltd
COIN
SKUUST
Sakura
BIT
UB8R4M
Unicredit Bank
NASDAQ
OLITW
OmniLit Acquisition
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten